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AIMS AND OBJECTIVES 
 
 
1. Evaluate the clinical and bacteriological profile of chronic pharyngitis in adults. 
2. To establish the role of atypical bacteria in chronic pharyngitis. 
        
 
 
 
 
 
 
 
 
 
Abstract 
 
Evaluation of the clinical and microbiological profile of patients with chronic 
pharyngitis with special emphasis on role of atypical organisms 
 
 
Objectives/Hypothesis: 
 
To study the clinical and microbiological profile of patients with chronic pharyngitis with 
special emphasis on role of atypical organisms such as Chlamydia 
pneumoniae,Mycoplasma pneumoniae and Fusobacterium necrophorum.  
 
Study design:  
A prospective case control study.  
 
Methods:  
344 patients with chronic pharyngitis were clinically evaluated to exclude non infectious 
causes of pharyngitis. Of these, 71 patients in whom comprehensive 
otorhinolaryngological examination did not elicit any factor contributing to the chronic 
pharyngeal complaint were recruited as cases and healthy asymptomatic adults were 
taken in the control arm. Both groups underwent throat swab for aerobic and anaerobic 
culture and ELISA to detect IgA antibodies against Chlamydia pneumoniae and 
mycoplasma pneumoniae.  
 
Results:  
Thirty-five of the 71 patients (49.3%) and 16 of the 71 control subjects (22.5%) were 
found to be seropositive for Chlamydia pneumoniae. Anaerobic organisms including 
Fusobacterium spp. were found to be significantly lower in cases as compared to controsl 
(p =0.041).There was no significant difference between cases and controls in aerobic 
culture growth and seropositivity to Mycoplasma pneumoniae. Patients with chronic 
pharyngitis were found to have a significantly higher rate of C.pneumoniae seropositivity 
than the control group (p = 0.001). 
 
Conclusions:  
Infection with Chlamydia pneumoniae seems to be a significant etiological factor for 
chronic pharyngitis. 
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INTRODUCTION 
 Sore throat is a common clinical condition seen by general practitioners and ENT 
physicians.  According to western figures approximately10% of the population present to the 
general practitioner with throat complaints for which a diagnosis of pharyngitis is made(1). 
Pharyngitis accounts for over 40 million visits by adults to medical facilities each year in the 
United States where it accounts for over 100 million days of absence from the workplace 
annually(2). The impact of this disease condition in the Indian scenario has not been ascertained. 
 
 In all otorhinolaryngology outpatient clinics the most common complaint among patients 
is persistent sore throat and the most frequent diagnosis is chronic pharyngitis with the 
underlying etiology unclear in most cases(3). Despite numerous consultations and countless 
investigations they often fail to achieve relief of their symptoms .These patients are evaluated for 
a possible infectious etiology failing which an irritant cause is contemplated. Pharynx being a 
common conduit for the nasal, oral and respiratory passages is exposed to panoply of irritants 
which can incite pharyngeal inflammation. Various possible etiological factors suggested are 
heavy smoking, occupational irritants, sinusitis with post nasal drip, mouth breathing, acid reflux 
and poor dental hygiene .Elimination of the inciting cause and treatment of infection with 
antibiotics are suggested remedies. However despite detailed evaluation and many diagnostic 
procedures, the most common scenario is a patient with persistent sore throat and no discernible 
aetiology.   
 
 
 Recently there have been reports of agents such as Chlamydophila pneumoniae, 
Mycoplasma pneumoniae, and anaerobic bacteria such as Fusobacterium necrophorum, which 
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are potentially treatable by currently available antibacterials – playing a role in chronic 
pharyngitis .However it has not been established whether they simply act as co-pathogens or as 
primary etiological agents (4-6). 
 
 Though this diagnostic dilemma exists and is a significant source of morbidity and of 
course anxiety, there is a paucity of literature on this subject especially from India. Therefore, 
keeping this in mind we undertook a prospective study to look for other etiological agents in this 
condition. Elucidation of etiological agents can help in better understanding of the disease 
condition and better management of these patients.  
 
The pharynx is the garbage dump of the bronchial 
tubes and the nasal passages. 
       - Sir William Osler 
 
 
 
 
 
 
 
   7
REVIEW OF LITERATURE 
 Chronic pharyngitis is defined as a chronic inflammation of the pharyngeal mucosa in 
which the pharyngeal mucosa may appear granular or hypertrophied (3, 7). Although this is a very 
common clinical situation the underlying etiopathogenesis and case definition especially in terms 
of duration of symptoms still continue to be controversial(3). The paucity of literature on this 
subject compounds to the management of this problem. Chronic pharyngitis is most often 
defined by its most predominant symptom i.e. persistent sore throat and the presence of 
prominent lymphoid tissue in pharynx (7). 
 Chronic pharyngitis is a term frequently used synonymously with chronic tonsillitis, 
although in reality it is a spectrum of conditions, from chronic inflammation localized primarily 
to tonsils to generalized inflammation of the whole pharynx (7).  
Anatomy of Pharynx 
 The pharynx is a conical fibro muscular tube that extends from base of skull to 
oesophagus. It is anatomically divided into: 
Nasopharynx – It is the uppermost part of the pharynx that lies behind the nasal cavity from the 
skull base to the level of the horizontal plane passing through the hard palate. 
Oropharynx – Part of the pharynx opposite the oral cavity from the plane of the hard palate 
above to the hyoid bone below. 
Laryngopharynx – It is the lowest part of the pharynx from the level of the hyoid bone to the 
lower border of cricoid cartilage. 
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The structure of the pharyngeal wall from within outwards consists of 
1. Mucous membrane - The Pharynx is lined by squamous epithelium except the nasopharynx 
which is lined by columnar ciliated epithelium. 
2. Sub mucosa 
3. Pharyngobasilar fascia – It is a fibrous sheet, deep to the pharyngeal muscles. It is thick in 
the upper part where it bridges the gap between upper border of the superior constrictor and 
the base of skull. Posteriorly, it thickens to form the pharyngeal raphe.  
4. Muscular coat – Consists of an outer circular layer made up of three constrictors and a 
longitudinal layer made up of stylopharyngeus, salpingopharyngeus and palatopharyngeus. 
5. Buccopharyngeal fascia - It covers the outer surface of constrictors. Beneath the 
buccopharyngeal fascia, on the muscular coat is found the pharyngeal plexus of veins and 
nerves. 
 Situated in the subepithelial layer are aggregates of lymphoid tissue arranged in the form 
of a ring which function as barrier to infection in first few years of life. These include the 
adenoids, paired tubal tonsils around Eustachian tube orifice, palatine tonsils, lingual tonsils, the 
lateral pharyngeal bands and follicles in the posterior pharyngeal wall. Localised inflammation in 
any one of these lymphoid tissues is referred by specific terms such as adenoiditis, tonsillitis etc. 
However when the entire mucous membrane of the pharynx is involved it is termed as 
pharyngitis. Generally this is accompanied by inflammatory enlargement of the lymph follicles 
in the tonsils, when it is termed as tonsillopharyngitis (7). 
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Pathophysiology of pharyngitis 
 Acute pharyngitis is a sudden onset inflammation of the pharynx and is most commonly 
viral in nature. The exact duration demarcating acute from chronic has not been defined. It is 
characterized by initial hyperaemia followed by oedema of the mucous membrane and increased 
secretion from the mucosal glands. Usually it is accompanied by inflammatory enlargement of 
the lymph follicles in the tonsils, when it is termed as acute tonsillopharyngitis.  
 Chronic pharyngitis is a chronic inflammation of the pharyngeal mucosa in which the 
pharyngeal mucosa may appear granular, oedematous or hypertrophied. Here there is 
proliferation of the connective tissue cells of the pharynx with hypertrophy of the mucosal glands 
.The hypertrophy of the sub epithelial lymphoid follicles gives it a granular appearance. When 
the proliferation of connective tissue progresses to a marked degree, fibrous bands and nodules 
may form. Hyperplasia of the mucous membrane in chronic pharyngitis makes it rigid and 
thereby causes pain and difficulty in swallowing. The hyperaemia of the small vessels leads to an 
alteration in the composition and diminution of the mucus secreted. Consequently such patients 
often complain of dryness of throat and a pricking sensation in the throat which may be 
associated with a dry harsh cough. There is a tendency of mucus plugs to aggregate on the 
surface which instead of effortlessly being propelled by the cilia is only expectorated by much 
coughing or hawking. There is an accumulation of secretions which if allowed to remain, 
propagates the vicious cycle of irritation and inflammation (8). Occasionally instead of 
hypertrophy there is atrophy of the mucosa and glands called as atrophic pharyngitis or 
pharyngitis sicca.  
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Normal Flora of pharynx  
 The normal flora of the pharynx consists of a plethora of aerobic and anaerobic 
organisms. In healthy individuals, the oropharyngeal flora consists of α haemolytic streptococci, 
non pathogenic Neisseria and low numbers of Streptococcus pyogenes, Streptococcus 
pneumoniae, Haemophilus influenzae, Staphylococcus. aureus, Moraxella catarrhalis, 
Fusobacterium spp. including Fusobacterium nucleatum , members of the genus Prevotella, 
Porphyromonas, anaerobic gram positive cocci like Peptostreptococcus spp. Actinomyces 
israelii, Candida albicans, adenoviruses and herpes simplex virus (9). In normal individuals, the 
anaerobes outnumber aerobes 100:1 in the oropharynx (10).  
Bacteriology of pharyngitis 
 Viruses are responsible for 85% to 95% of acute pharyngitis in adults. The main 
aetiological agents are adenovirus and respiratory syncytial virus (RSV).The most important 
bacterial cause of a throat infection is group A β-haemolytic streptococcus (GABHS), which is 
responsible for about 10% of sore throats in adults (11). Antimicrobial therapy is of no proven 
benefit in the treatment of acute pharyngitis due to bacteria other than Group A streptococci, 
Corynebacterium diptheriae and Neisseria gonorrheae. Despite this there is an over prescription 
of antibiotics leading to emergence of antibiotic resistance, besides exposing the patient to 
potential adverse effects of such therapy (12). 
 
 The microbiological profile of chronic pharyngitis is not well documented. The 
bacteriology of chronic pharyngitis on the other hand had been well studied. Group A β -
haemolytic streptococci is the most common bacterial pathogen causing chronic tonsillitis. These 
organisms are believed to reside in the crypts of the tonsils forming micro abscesses which can 
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cause recurrent episodes of tonsillitis (13). Other organisms implicated are staphylococcus aureus, 
streptococci pneumuniae.There are no studies describing the microbiological profile of chronic 
pharyngitis. 
Clinical profile 
The clinical profile of acute pharyngitis is fairly similar in children and adults.  
The clinical picture in adults is characterized by an abrupt onset of the following: 
 
• Sudden onset of sore throat associated with difficulty in swallowing 
 
• Fever moderate (39-40.5°C) 
 
• Chills maybe present but rigors rare 
 
• Malaise, Headache 
 
• Abdominal pain ,nausea and vomiting may be seen in children 
 
 Signs include tonsillopharyngeal erythema, tonsillopharyngeal exudate, softpalate 
petechiae, swollen uvula and swollen and tender anterior cervical lymph nodes (12). 
 
 Chronic pharyngitis on the other hand present with mild persistent throat pain or 
irritation. They may present with mild difficulty in swallowing with hawking sensation .Clinical 
examination reveals granular posterior pharyngeal wall .Thickening of lateral pharyngeal wall 
and edema of the pharyngeal mucosa with stasis of secretions may be present 
 
Etiological classification 
 Chronic pharyngitis is divided into two types based on the whether a definite etiological 
agent is detected. The two types are 
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1. Chronic specific pharyngitis - When the condition is secondary to a primary infection by 
specific micro organisms like Treponema pallidum, Mycobacterium tuberculosis Mycobacterium 
leprae and others, this is termed as chronic specific pharyngitis(7). These micro organisms 
generally cause systemic disease with involvement of more than one organ system.   
 2. Chronic non specific pharyngitis - When no definite pathogenic organism is identified as 
etiology of pharyngitis it is termed as non specific pharyngitis. Patient presents with history of 
long standing throat discomfort without any evidence of specific etiological factor, and often 
with little to suggest on clinical examination apart from prominent lymphoid tissue in the 
pharynx. Various possible etiological factors suggested are heavy smoking, occupational 
irritants, chronic sinusitis with post nasal drip, mouth breathing, acid reflux and poor dental 
hygiene. Evaluation of such patients requires a careful history and detailed examination of the 
nose, oral cavity, oropharynx, larynx, pharynx and neck. Exclusion of malignancy is the most 
important aspect of managing these patients (7).  
Chronic specific pharyngitis 
Syphilis:  
Syphilis is a sexually or congenitally transmitted infection caused by spirochaete, Treponema 
pallidum which progresses through primary, secondary and tertiary stages. It is the secondary 
stage which usually gives rise to pharyngeal symptoms (14).  
The primary stage is characterized by a chancre most commonly seen in the genital area although 
occasionally it can affect extra genital areas such as the pharynx (7). The lesion begins as a papule 
which breaks down to form a painless ulcer with indurated margins. The ulcer persists for two to 
six weeks and resolves spontaneously (13).  
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 Secondary syphilis occurs four to six weeks after the primary lesion and is characterized 
by fever, malaise, headache and mucocutaneous rash. Sore throat occurs in about 30% of such 
cases (6). The pharynx appears inflamed and hyperaemic with lesions classically described as 
mucous patches or ‘snail-track’ ulcers.  These ulcers are more common in the oral cavity than in 
the oropharynx and are usually covered with a grayish white membrane which when scraped has 
a pink base. In contrast, to other membranes, scraping away of this membrane does not lead to 
bleeding (5).  This stage lasts for a few weeks and the lesions are highly infectious. 
 
 Tertiary syphilis develops in 30 % of untreated patients 5-25 years following primary 
infection. It typically manifests as a gummatous lesion involving any part of the body. It can 
occur in the hard palate, nasal septum, tonsil and posterior pharyngeal wall as a granulomatous 
lesion that begins as a nodule and breaks down to form an ulcer (14).  
 Serological tests are the mainstay of diagnosing syphilis. The VDRL test (Venereal 
Disease Research Laboratory test) is the screening test used and the TPPA (Treponema Particle 
Agglutination Test) which uses treponemal antigens is used as a confirmatory test (13). Once 
diagnosed, treatment is with Benzathine penicillin, 2.4 million units, intramuscular given as a 
single dose for primary or secondary syphilis. In tertiary syphilis, crystalline penicillin is 
preferred at dosages recommended by the CDC in 2006 (14).   
Tuberculosis  
 The pharynx is a common site for tuberculous infection in children. They usually present 
with an asymptomatic focus in the tonsil or adenoid with associated cervical lymphadenopathy. 
Secondary TB affecting the pharynx usually occurs in highly sputum positive patients with 
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massive cavitating pulmonary lesions. It manifests as multiple, shallow, painful ulcers in the 
pharynx or oral cavity. The problem has been compounded in recent years with rise of the HIV 
epidemic and the resurgence of TB closely following the epidemic (7). Diagnosis is made easily 
because of clinical and radiological correlation with pulmonary TB. Microscopic examination of 
the stained smears remains the gold standard of diagnosis despite introduction of newer tests like 
PCR. The treatment is the anti-tuberculous regime as per the RNTCP (Revised National 
Tuberculosis Control Programme) category and protocol. 
Toxoplasmosis  
 Toxoplasmosis is a rare disease caused by Toxoplasma gondii which in the early stage 
can manifest as sore throat with malaise, fever and cervical lymphadenopathy. In India, Sundar 
et al have reported a prevalence of 26% in healthy blood donors (15). Toxoplasmosis occurs both 
in the immunocompetent and the immunocompromised and as expected is more severe in the 
latter. Organs most commonly affected are the CNS, heart and eye especially in children with 
congenital infection. Pharyngeal infection with this agent is rare and clinically resembles 
infectious mononucleosis (16).  Kardon et al found that out of 22 tonsillar granulomas subjected to 
histopathological evaluation only one was due to toxoplasmosis (17).  
 
 In immunocompetent individuals the disease is usually self limiting .However in 
immunocompromised patients it can lead to encephalitis and space occupying lesions in the 
brain. The former group of patients needs no treatment but the latter may need combination 
therapy with pyrimethamine and sulphadiazine or azithromycin (7).  
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Leprosy  
 Leprosy is a chronic condition caused by Mycobacterium leprae which not only affects 
the skin and peripheral nerves, but also the respiratory mucosa and eyes. Isolated involvement of 
the pharynx is rare, it usually occurs secondary to nasal infection where it gives rise to 
granulomatous lesions ulcerating and healing with fibrosis. Treatment is multidrug therapy with 
dapsone and rifampicin (7).  
Scleroma 
 It is a chronic infection caused by Klebsiella rhinoscleromatosis which primarily affects 
the nose and from there can spread to the pharynx where it produces granulomatous lesion which 
heals by scarring (7).  
Candidiasis 
 Candida albicans which is usually normal pharyngeal flora may become pathogenic 
when there are some local or systemic changes in the host. The most common symptom is pain 
and dysphagia while examination reveals small curdy white patch which when removed leaves 
an erythematous lesion. Candidiasis with local predisposing factors responds to local therapy 
with nystatin drops and lozenges 1,00,000 units six hourly (7). 
HIV and AIDS 
 Both the primary HIV infection and the full blown AIDS syndrome can manifest with 
pharyngeal involvement. Acute seroconversion can present as fever, pharyngitis, malaise, 
maculopapular rash and cervical lymphadenopathy similar to glandular fever. Opportunistic 
infections with Candida, TB, syphilis and CMV are seen. Lymphoid hyperplasia of all the tissues 
of the waldeyer’s ring is seen which if present in the nasopharynx requires biopsy to exclude 
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malignancy. AIDS defining malignancies like Non Hodgkins lymphoma, Kaposi’s sarcoma, 
Squamous cell carcinoma and Hodgkins lymphoma can also be seen. Treatment is anti retro viral 
therapy and prophylaxis for opportunistic infections (7).  
Chronic Nonspecific Pharyngitis 
Laryngopharyngeal reflux 
 Gastro-oesophageal reflux disease (GERD) is defined by oesophageal symptoms or 
mucosal damage produced by abnormal reflux of gastric contents into the oesophagus (18). 
 Laryngopharyngeal reflux (LPR) or reflux laryngitis is one of the most common extra-
oesophageal manifestations of GERD (18,19).  
 Population based studies found that the prevalence of symptoms attributed to LPR was in 
the range of 15% to 20% (20, 21). De Vault (2000) and Postma et al (2002) have stated that up to 
15% of all visits to the otolaryngology clinics are because of manifestations of LPR (22, 23). 
Aetiology of GERD and LPR 
 The aetiology of GERD and LPR is multifactorial, including oesophageal sphincter 
function, exposure time, and tissue sensitivity. It has previously been shown that laryngeal 
epithelium is more sensitive to gastric reflux than oesophageal epithelium. The number of 
episodes of reflux required to cause disease in the larynx are lower, so that even three reflux 
episodes (pH 4.0) per week are likely to cause LPR. In contrast as many as 50 episodes per week 
are needed for GERD to manifest (24, 25). The basis of this increased sensitivity remains poorly 
understood, but it is thought that the presence of a low pH in the larynx coupled with pepsin 
causes a change in the reaction of stress proteins in regard to epithelial damage repair, resulting 
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in damage not seen so readily in the oesophagus. This allows a minimal amount of gastric reflux 
to cause LPR. 
Clinical features and diagnosis of LPR 
 Common throat symptoms attributed to LPR include hoarseness, vocal fatigue, frequent 
throat clearing, nocturnal laryngospasm, chronic cough, dysphagia, and globus. Chronic 
laryngitis and a difficult-to-treat sore throat are associated with acid reflux in as many as 60% of 
patients (1, 26-31). 
 However, many of these symptoms are non-specific and may be found in other conditions 
such as smoking, allergies and postnasal drip. The presence of the aforementioned symptoms in 
addition to detection of edema and erythema of the posterior glottis by laryngoscopic 
examination is considered to be suggestive of LPR. However the controversies in the literature 
regarding the diagnostic criteria of LPR make the task quite complicated (32-34). Some studies 
presume that mucus stasis, erythema, edema, hypertrophy, ulceration, and granulation of the 
posterior larynx (arytenoids, interarytenoid notch) are sufficient for diagnosis of LPR (24, 35,36)  
while others suggest that similar pathological changes in posterior larynx may be present among 
persons without LPR (34, 35, 37).  
 According to Reulbach study (n=100), signs of LPR were determined in 64% of the 
community- based cohort of healthy adults over 40 years of age.  In the cohort of people he 
examined, only 12% of them had a completely normal laryngeal examination (37). Vavricka et al 
(n=132) and Hicks et al (n=105) have found few signs of LPR in 85-87% of the healthy 
volunteers (34,35). The predicament in diagnosing GERD-related laryngeal and pharyngeal 
abnormalities is that the examination is subjective and based on the experience of the physician 
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identifying these potentially acid-related laryngeal and vocal fold lesions. Intuitively, this 
approach may result in considerable variations among physician’s diagnosis of reflux laryngitis. 
This may explain the inconsistent treatment results with proton pump inhibitors (PPI) and anti 
reflux measures, as the diagnostic criteria used in the first place are subjective and may vary with 
different physicians.  
 Thus solving the dilemma of an ideal diagnostic modality for LPR appears as one of the 
“key stones” in solving the problem.  
 The LPR scoring system is a self administered tool described and validated by Belafsky 
et al (2002), which entails patients to use a 0- to 5-point scale to grade the following symptoms: 
(1) hoarseness or voice change,(2) frequent throat clearing, (3) excess throat mucus or postnasal 
drip, (4) difficulty swallowing, (5) coughing after eating or lying down, (6) breathing difficulties 
or choking spells, (7) troublesome or annoying cough, (8) sensation of something sticking or a 
lump in the throat, and (9) heartburn, chest pain, indigestion, or stomach acid coming up. 
 The Reflux Symptom Index score greater than 13 is considered abnormal and suggestive 
of LPR (38). This scoring system has been widely used by various authors and thus a combination 
of focused history taking and specific findings on flexible nasopharygolaryngoscopy is the most 
reliable method of LPR diagnosis.  
Treatment 
 The first approach for management of LPR patients is standard dose Proton pump 
inhibitor (PPI) therapy combined with lifestyle measures. In the case of adequate response after 3 
to 6 months, the dose can be titrated to determine the minimal required maintenance dose (39). In 
those who do not respond favourably to short term standard dose PPI therapy, it is advisable to 
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stop PPI therapy, and to perform gastro endoscopic examination, preferably four weeks after 
cessation of therapy. Antireflux surgery may be considered in patients with a previous good 
symptomatic response to PPI therapy who require chronic PPI therapy, or in patients with an 
insufficient response to PPI therapy in whom a convincing relationship between reflux and 
symptoms or lesions has been demonstrated. Despite all these measures many authors have 
reported treatment failures. This could be because of non adherence to lifestyle modification 
measures. Recently, Beaver and Karow have suggested that patients with allergy or silent 
laryngopharyngeal reflux in addition to pre-existing laryngotracheal inflammation may be more 
susceptible to prolonged airway inflammation when an infection with any of the atypical 
organisms like Mycoplasma, Bordetella or Chlamydia occurs (4).  
 
Postnasal drip secondary to allergic rhinitis and chronic sinusitis 
 Allergic rhinitis and chronic rhino sinusitis are the other common causes of persistent 
sore throat. .Allergic rhinitis is an IgE mediated condition in which mast cells and basophils 
respond to the triggering stimulus by inducing degranulation and release of inflammatory 
mediators such as histamine. These are responsible for the typical symptoms of nasal congestion, 
excessive sneezing and watery nasal discharge. Occasionally it may present only as nasal 
stuffiness and a persistent postnasal drip with constant hawking sensation. Chronic sinusitis 
especially of the posterior group of sinuses usually presents as postnasal drip, with hawking and 
even halitosis. Evaluation of any patient with chronic throat irritation entails a thorough history 
of nasal symptoms and a rigid nasal endoscopy to look for signs of sinusitis. Endoscopic 
evaluation is the key to diagnosis of chronic rhino sinusitis as it provides precise information on 
quality of nasal mucosa and presence of secretions and discharge (40,41). X-ray of the paranasal 
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sinuses gives a high false negative rate (42) and cannot be considered reliable to rule out sinusitis 
especially in mild cases of sinusitis. 
 
 The treatment of allergic rhinitis entails anti allergic measures along with steroid nasal 
sprays. Chronic sinusitis is of multifactorial aetiology comprising a vicious cycle of 
pathophysiological and anatomical factors. Treatment is aimed at reducing mucosal 
inflammation, controlling infection and restoring aeration of nasal and sinus mucosa. If 
symptoms continue functional endoscopic sinus surgery should be considered (2). 
 
Occupational and environmental irritants 
 Environmental pollution with plethora of pollutants is a known irritant for the respiratory 
and pharyngeal mucosa. Workers in certain occupations like printing and dye industry, 
automobile industry are predisposed to pharyngeal irritation. 
 Printing workers are exposed to panoply of potentially toxic substances, including 
pigments, inks, solvents, resins, driers, plasticisers and wetting agents (43) which might have a 
direct irritant effect and produce chronic pharyngitis or sinusitis. Sama et al (1997) observed that 
in the automobile industry compounds containing chlorine, chromium, nickel and sulfur are 
mucosal irritants (44). 
 
Dental sepsis 
 Chronic periodontitis or inflammation of the periodontal membrane is a condition 
frequently seen in adults, usually smokers where an abnormal pocket develops between the tooth 
and gum with deposition of debris and pus. This may manifest as bleeding, halitosis, foul taste 
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and throat irritation. Treatment is improved oral hygiene with surgical removal of pocket wall 
and diseased tissue (45). 
 
Smoking  
 Tobacco consumption and smoking including passive smoking are direct irritants to the 
oral, pharyngeal and respiratory mucosa. In addition to chemicals such as 4-Aminobiphenyl 
Benzene, Cadmium, Chromium, 2-Napthyalmine and Nickel which are known carcinogens, it 
has other constituents like Benzoantracene and Benzopyrene which are mucosal irritants (7). 
 Despite a detailed evaluation, the most common clinical scenario is an individual with 
sore throat in whom no etiological factor is discernable .This in turn renders treatment difficult or 
ineffectual as the primary cause remains undiagnosed (5). Such people are often thought to be 
malingering and even referred to the Psychiatry department for assessment (46).   
 In recent times there have been reports of non-streptococcal agents such as 
Chlamydophila pneumoniae, Mycoplasma pneumoniae, anaerobic bacteria such as 
Fusobacterium necrophorum, which are potentially treatable by currently available antibacterials 
– playing a role in chronic pharyngitis .It has not been established whether they simply act as co 
pathogens or as primary etiological agents (5,6, 47)   
Fusobacterium necrophorum 
 Fusobacterium necrophorum is an anaerobic non-sporing, gram negative bacilli which 
belong to the family Bacteriodiaceae. Their nomenclature as fusobacteria is derived from their 
morphology which is spindle shaped or fusiform. Infections caused by these organisms are 
amenable to treatment with metronidazole (48).  
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Fusobacterium as normal flora in the oropharynx 
 Fusobacteria are found in the mouth, genitourinary and gastrointestinal tract of normal 
individuals (49).  Although various studies have been done to study the anaerobic flora of the 
mouth, the isolation of Fusobacterium necrophorum has been rare (45). Moore et al (1982) found 
no evidence of F.necrophorum in samples of gingival fluid whereas Brazier et al (2002) isolated 
fusobacteria from nine of sixteen healthy adults (50, 51). Tanaka et al did not isolate 
F.necrophorum from the oropharynx of any of their patients (52). Most common fusobacterium 
identified as a normal commensal in all these studies was F.nucleatum and F.necrophorum was 
rarely detected. However in a recent study, Jensen et al (2007) detected F.necrophorum in the 
throats of 21% of healthy individuals by PCR techniques (53). The categorisation of 
fusobacterium as a commensal or pathogenic organism is difficult to ascertain from literature 
because of the inconsistent methodologies used for their isolation and identification (54). 
 
Fusobacterium and Lemierre’s syndrome 
 Lemierre’s disease is an acute infection where there is thrombophlebitis of internal 
jugular vein following an acute sore throat. Fusobacterium necrophorum and other fusobacteria 
are important causes of this septicemic illness which presents with metastatic abscesses. This 
disease was initially noticed in young people by Courmont and Cade in the early part of the last 
century. Lemierre described in detail the illness as we know it today in 1936 and the syndrome is 
therefore named after him. Lemierre’s syndrome is also known to occur following tonsillitis, 
pharyngitis, mastoiditis, and infection of the teeth and gums. Lemierre’s syndrome was 
particularly recognized in the preantibiotic era as a complication of pharyngitis with 
parapharyngeal abscess and was rarely reported in the literature during the 1960s and 1970s, 
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when penicillin came into common use .This disease had become uncommon in the ‘antibiotic 
era’ presumably due to empirical antibiotic therapy, leading to its description as the forgotten 
disease. In recent decades, however, an increasing number of reports of Lemierre’s syndrome in 
children have been published (55). 
 
Fusobacterium and persistent sore throat 
 In recent times, Batty et al (2004) have opined that these organisms are responsible for 
longstanding sore throat in the general population. They isolated F.necrophorum from 21% of 
patients with persistent sore throat. The strains isolated from these cases were very similar in 
character to the ones that cause Lemierre's disease (6). Jensen et al found F.necrophorum in 49% 
of patients with chronic tonsillitis as compared to 21% on controls by PCR technique (53). This 
recent evidence strongly suggests that F.necrophorum has a causative role in non streptococcal 
tonsillitis. However further studies need to be conducted to substantiate its etiological role. 
 
Chlamydophila pneumoniae 
Chlamydia pneumoniae also known as Chlamydophila pneumoniae (56) is an obligate intra-
cellular bacteria which infects mainly ciliated epithelial cells and alveolar macrophages (57). The 
life cycle involves two forms, the elementary body (EB) which is the infective form and the 
reticulate body which is the form that replicates in the host cell (58).  
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Epidemiology 
 Humans are the only known reservoir of Chlamydia infections.  Person to person 
transmission occurs via respiratory secretions (59) especially among close contacts (60) more so in 
conditions of high relative humidity (58). C. pneumoniae is one of the important causes of 
infections of the respiratory tract such as sinusitis, bronchitis and pneumonia (61).  It is estimated 
that roughly about 10% of community-acquired pneumonia cases and 5% of bronchitis and 
sinusitis cases are caused by this organism. It is said to be involved in the pathogenesis and also 
exacerbation of asthma and chronic obstructive pulmonary disease (58). 
 
 C pneumoniae has also been thought to be the agent responsible for persistent cough both 
in children and adults (62, 63). Enough evidence has accumulated to associate this organism with 
atherosclerosis (64). C. pneumoniae is also implicated in causing late-onset Alzheimer’s disease.  
Asymptomatic infection of the upper respiratory tract persisting for long periods of time has also 
been documented (58).  It has been reported that C. pneumoniae can persist in the nasopharynx for 
a prolonged period subsequent to acute infection of the respiratory tract. Around 5% of healthy 
adults and children have been documented to have asymptomatic infection (64).  
 Re-infection and re-activation are thought to be common. It is estimated that as many as 
80% of the world’s population would have been infected with this agent at some stage in their 
life time (61). Recurrent chlamydial disease may result from either repeated infections or 
persistence of the organism after unresolved infections. Indeed, the high incidence of chlamydial 
infections and transient immunity typically observed after infection present difficulties in 
differentiating between persistent infection and re-infection. Presence of high IgA antibodies to 
C. pneumoniae titres is indicative of persistent antigenic stimulation by an ongoing infection as 
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IgA antibodies are short-lived (64, 65). Detection of IgG antibodies cannot be used to indicate 
persistent infection as these antibodies remain elevated for a long time after recovery from an 
acute infection.  
 
Diagnosis of Infections  
 Cell culture is considered as the gold standard for diagnosis of C. pneumoniae infections. 
The microimmunofluorescence (MIF) is the serological reference standard. Enzyme linked 
Immunosorbent Assay’s [ELISA] has been used with variable success to detect IgM, IgG and 
IgA antibodies to the immunodominant MOMP (major outer membrane protein). Results are 
similar to those observed by MIF (59, 64). 
 
Role in chronic pharyngitis 
 The role of Chlamydia pneumoniae in chronic pharyngitis is still to be completely 
elucidated. In a study by Falck et al, 12 patients with longstanding throat symptoms, who were 
also positive by PCR (polymerase chain reaction) for C. pneumoniae were selected for a 
longitudinal study to determine whether C. pneumoniae is an aetiological agent for chronic 
pharyngitis. Nine of twelve patients showed positive IgA antibodies against C. pneumoniae.  In 
eight of the nine patient’s positive for IgA antibody, the antibodies persisted over the follow up 
period of around 2 years (5). Two patients who were initially negative for C. pneumoniae became 
positive when they suffered a relapse. This showed a positive correlation between persistent 
symptoms and an increased serological titre towards C. pneumoniae. These results support the 
finding that IgA antibodies are reliable markers for evaluating a reinfection or a persisting 
infection. The same opinion has been expressed by Blasi et al (65). The biopsies taken from the 
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granulations on the posterior pharyngeal wall demonstrated the organism by 
immunohistochemisty in 9 of their 12 patients. Although their study was limited by small sample 
size (n=12) and the lack of controls, it showed a causative role of C.pneumoniae in chronic 
pharyngitis (65). Elevated IgA titres have been considered a reliable marker of chronic infection 
with C. pneumoniae in chronic bronchitis and coronary heart disease (5). 
Treatment 
 Falck et al and others (5) have reported the difficulty in treating persistent C. pneumoniae 
infections with antibiotics. Hammerschlag and others (66) have observed that the finding of                
C. pneumoniae in culture after treatment is a common event in patients who show a clinical 
improvement. Their patients showed clinical improvement while on antibiotics, and for short 
periods of weeks to a few months after treatment, but relapsed regardless of the type of antibiotic 
administered. They found that some patients with persisting infection required multiple courses 
of antibiotic treatment, and have not found an optimal treatment regimen. Roblin et al. (67) 
demonstrated that persistence of C. pneumoniae is not secondary to the development of 
resistance to antibiotics. Only actively growing chlamydial forms are affected by antibiotics that 
penetrate intracellular spaces like the macrolides or tetracyclines. The infectious particle of 
chlamydia, the elementary body, is metabolically inert and therefore resistant to the action of 
bacteriostatic antibiotics such as macrolides and tetracyclines. Eradication of C. pneumoniae in 
patients with chronic pharyngitis is seldom achieved by a single course of antibiotic (68) 
Clarithromycin and erythromycin show good in vitro activity, and so far have been the most 
commonly employed drugs in the treatment of C. pneumoniae infection. Newer macrolides, 
tetracyclines and fluoroquinolones are other potentially effective drugs although their efficacy 
has only been shown invitro studies and may not be replicated invivo.  Falck et al have suggested 
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that natural immune mechanisms may in most patients eradicate remaining organisms over a 
period of time (5). 
     
Mycoplasma pneumoniae 
 Mycoplasmas are the smallest free living organisms and are included within the class 
Mollicutes [“Mollis=soft, cutis= skin”] (69). The term ‘Mycoplasma’ has been derived from Greek 
word mykes meaning fungus and plasma denoting something that is moulded (70). Chanock et al 
proposed the name Mycoplasma pneumoniae in 1963 for this organism (71). They lack a rigid cell 
wall and hence are pleiomorphic. Though they are free living organisms they require serum for 
growth. On agar containing media, colonies are produced which are opaque at the centre and 
translucent in the periphery, producing the characteristic “fried egg colonies” appearance (70).  
 
 M pneumoniae causes upper and lower respiratory tract infections in all age groups. 
Infections are most predominant in the 5-20 year age group. The ciliated epithelial cells and 
alveolar macrophages are preferentially infected by this organism (72). Infection occurs by 
adherence to the host cell through a network of adhesins and other proteins. Production of 
hydrogen peroxide by this bacterial agent is responsible for the injury or damage to the host cell 
(73).  
Epidemiology  
 Infection is acquired by inhalation of aerosols. Hence, person-person transmission does 
occur, especially among the household contacts and in closed communities especially military 
barracks.  M. pneumoniae infects all age groups around the world, but children are more likely to 
develop pneumonia. Every few years it gives rise to epidemics. 
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Clinical syndromes caused by Mycoplasma pneumoniae  
 In children above the age of 5 years, upper respiratory tract infections are the most 
common followed by tracheobronchitis and pneumonia. (73). Cough is the clinical hallmark of 
respiratory infections caused by Mycoplasma pneumoniae (74). It is also implicated in 
exacerbating asthma and chronic bronchitis (70).  
 Other than infections of the respiratory tract including acute exacerbations of asthma and 
chronic obstructive pulmonary disease, Mycoplasma pneumoniae can cause extra-pulmonary 
diseases in children also. Most of the extra-pulmonary lesions due to Mycoplasma pneumoniae 
are thought to occur due to immune complex mechanism or due to development of auto-
antibodies. These include autoimmune haemolytic anaemia, acute glomerulonephritis, renal 
failure, tubulointerstitial nephritis, IgA nephropathy and neurological complications such as 
encephalitis, cerebellar syndrome, polyradiculitis and cranial nerve palsies (73, 74).  Moreover it is 
thought to cause erythema multiforme, arthralgia and arthritis. It is also suspected to cause digital 
necrosis in patients with sickle cell disease (73).   
Role in chronic pharyngitis 
 Infection with Mycoplasma pneumonia is common in patients who present with 
hoarseness, throat clearing, globus, and cough, regardless of the duration of the symptoms. In a 
study by Beaver and Karow et al, 15%of such patients had elevated IgM to Mycoplasma 
pneumoniae (4). The role of Mycoplasma pneumoniae in chronic pharyngitis is yet to be 
completely elucidated, although it is a known etiological agent of acute pharyngitis (6). 
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Diagnosis of infection 
 As mycoplasma lack a cell wall they are not detected by a Gram stain. In most 
laboratories, the simple but less sensitive cold agglutination test is the mainstay of diagnosis (75). 
ELISA to detect IgG & IgM antibodies are also used and have demonstrated a sensitivity and 
specificity of 99%. Culture is cumbersome, slow and has a sensitivity not exceeding 60% in the 
best laboratories, but it is 100 % specific (76). PCR is more useful in diagnosis especially when 
cultures are inconclusive. As most laboratories do not have culture facilities and the 
infrastructure and expertise to perform molecular assays, serological tests are used for diagnosis 
(73). 
 Chronic pharyngitis is a common clinical condition; however there is a paucity of data on 
its defining criteria and its etiopathogenesis. Determination of the causative agent and 
elucidation of its pathogenesis can result in effectual treatment and better patient satisfaction in 
addition to reducing the economic burden on the health care system. 
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MATERIALS AND METHODS 
Research design  
1. This is a descriptive study to determine the clinical and bacteriological profile of 
chronic pharyngitis. 
2. To study the role of atypical organisms in chronic pharyngitis, a prospective case 
control study design was adopted. 
Study duration 
 The study was performed on patients and controls over a period of 18 months from June 
2008 to October 2009 in the Department of ENT and Microbiology. The study was approved by 
the institutional review board of Christian Medical College, Vellore. All study procedures were 
performed after obtaining informed consent both from cases and controls as per the form 
attached in Appendix-A.  
Sample size  
This study was done on 72 patients The Sample size was calculated using the following formula:  
Sample size =   2 * p *q *(zα +zβ) ² / d² 
 
 This sample size of 72 was arrived at by assuming a difference of 20% in the prevalence 
of the offending organisms in chronic pharyngitis and normal controls. Batty et al (2004 have 
demonstrated a prevalence of   Fusobacterium necrophorum in 21% of cases with chronic sore 
throat and nil from healthy controls. C. pneumoniae prevalence has been noted in 12.9% of 
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healthy adults by serology (77). In the absence of data regarding the prevalence of these agents in 
the Indian population with chronic pharyngitis we extrapolated these findings to obtain the 
sample size of 72. As it was a case control study, an equal number of age and sex matched 
controls were taken to validate the findings. 
 Selection of study participants 
 Healthy individuals aged 17 and above who attended the ENT outpatients with 
complaints of pain or irritation in the throat for 3 months or more and who were willing were 
included in the study. A two page comprehensive questionnaire (Appendix-A) was given to each 
of them at the start of the study. The questionnaire consisted of demographic information and 
detailed medical history which included asthma, allergies, smoking, alcohol use, occupational 
irritants and reflux symptoms. 
 After a comprehensive history each of them underwent a detailed general examination 
and a thorough otorhinolaryngological examination.  
 Anterior rhinoscopy was done to look for signs of allergic rhinitis and sinusitis such as 
pale mucosa, mucoid discharge and post nasal drip, in the absence of which further, rigid nasal 
endoscopy (RNE) was done to rule out sinusitis. 
During oral examination each of their Posterior pharyngeal wall appearance was graded as 
1. Congested when it was erythematous in appearance   
2. Granular when there was presence of granulations, thickening of lateral pharyngeal 
bands and edema of the posterior pharyngeal wall is noted. 
3. Normal 
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Indirect laryngoscopy was done to rule out malignancy and also to look for signs of 
larngopharyngeal reflux. The common findings usually seen in LPR are 
1. Congestion of arytenoids,  
2. Edema of arytenoids and posterior glottis  
3. Interarytenoid granulations and heaping 
4. Ulceration in the posterior glottis and  arytenoids 
 
 Rigid nasal endoscopy was performed by a specialist who was blinded to group 
allocation. To ensure technical consistency, all examinations followed a standard protocol of 
subject instructions and tasks and used the same equipment. The Rigid nasal endoscope (Servell 
4mm zero degree) was illuminated by a xenon light source. The scopy was done to look for any 
evidence of sinusitis such as discharge, purulence and any collections. 
 Patients in whom detailed history taking and thorough clinical and endoscopic 
examination failed to reveal any cause for pharyngitis were taken as cases for the study. 
The inclusion and exclusion criteria for cases were as follows 
 Inclusion criteria 
1. Healthy adults aged 17 years  and above with complaints of persistent throat pain or 
irritation for more than 3 months  
2. Normal otorhinolaryngological examination 
3. Normal indirect laryngoscopy (IDL) 
4. Normal Diagnostic nasal endoscopy  (DNE)  
  
   33
Exclusion criteria 
Individuals who are/or have 
1. Immunocompromised 
2. Allergic rhino sinusitis 
3. Gastro-oesophageal reflux disease (GERD) 
4. Smokers 
5. Sinusitis on endoscopy  
6. Malignancies. 
 
 The study and procedure was first explained to each subject and informed consent was 
obtained (Appendix-B) by the principal investigator. 
 Two throat swabs for culture (aerobic and anaerobic) and 5 ml of venous blood for 
serological testing was collected from all subjects (cases and controls) by the principal 
investigator for uniformity. The posterior pharyngeal wall was swabbed without touching any 
adjacent structures. These swabs were immediately transported to the microbiology laboratory 
and without any delay processed according to the protocol followed for the same. Venous blood 
was collected in a clotted tube to obtain serum for the serological tests. 
 Controls were selected patients who presented to the OPD with non throat related 
conditions such as earlobe repair, migraine or were relatives of patients having no ENT 
complaints at all.  They were age and sex matched with the cases and included in the study if 
they had no history of throat pain or irritation for 3 months. After informed consent, throat swabs 
were taken for aerobic and anaerobic culture and venous sample for serological testing. The 
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samples were promptly delivered to the laboratory where they were plated and cultured as 
described below.  
 
The laboratory personnel were blinded regarding who were cases and controls. 
Culture protocol  
 Standard aerobic and anaerobic cultures to detect pathogens were performed in the 
Microbiology laboratory as per the standard current protocol followed for the same. The 
procedure followed has briefly been described  
Sample: Two throat swab samples were taken per case or control 
Aerobic culture  
For aerobic culture, the throat swab was inoculated onto a blood agar (BA) plate.  
Each BA plate was incubated at 370 C in an atmosphere of 5% CO2. The culture plates were read 
after 24 hours and 48 hours of incubation.  
If pathogens were isolated they were reported as soon as they were identified along with the 
antimicrobial susceptibility pattern.   
The pathogens looked for were β-haemolytic streptococci, Arcanobacterium hemolyticum, 
Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, 
Staphylococcus aureus.  
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Anaerobic culture  
 For anaerobic culture the swab was inoculated into blood agar (BA), neomycin blood 
agar (NBA), thioglycollate broth (TG) and Robertson’s cooked meat medium (RCM). Following 
inoculation the media were incubated in an anaerobic atmosphere at 370 C for 72 hours. Gram 
stains were done every 24 hours to detect growth in the thioglycollate broth (TG) and 
Robertson’s cooked meat medium (RCM). The plate media (BA & NBA) were checked after 72 
hours. If organisms were observed they were tested for aerotolerance (to prove that they were 
truly anaerobes). Identification and anti-microbial susceptibility testing was done as per the 
protocol currently followed.  
Serology 
Sample: Serum was obtained by collecting 5 ml venous blood from each subject into a clotted 
tube.  
Tests done:  
 ELISA tests to detect IgA antibodies to Chlamydophila pneumoniae and Mycoplasma 
pneumoniae was performed using commercially available kits [Euroimmun AG, Lubeck, 
Germany].   
Procedure in brief:  
 Diluted patient’s serum samples were incubated with antigen coated onto the wells in the 
ELISA plate. In case the sample was positive, specific IgA antibodies bound to the antigen. For 
the detection of the bound antibodies, a second incubation was carried out using an enzyme 
labelled anti-human IgA (enzyme conjugate) catalysing a colour reaction. The intensity of the 
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colour reaction developed was measured using the ELISA reader. The test was validated and 
interpreted as described by the manufacturer. 
 The clinical data and the results of the various microbiological tests were noted in the 
proforma designed for the same and the results were analysed 
 
Analysis of data 
 The data obtained from this study was analysed with SPSS Version 16.0. To calculate 
statistical significance the chi square test was applied for categorical data and the two sided t test 
for independent continuous data was used. 
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RESULTS 
 
 This prospective case control study was conducted in the ENT department of a tertiary 
care hospital. Between June 2008 and October 2009, a total of 344 individuals with clinical 
features suggestive of chronic pharyngitis were screened. Of these 71 who satisfied the inclusion 
and exclusion criteria were recruited as subjects. Given below is the clinical profile of the 
patients screened. 
Figure 1: Profile of patients with chronic pharyngtis 
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 Of the 344 adults with throat pain or irritation who were examined, 160 (46%) had 
features suggestive of GERD and 80 (23%) of allergic rhinitis.  A further 10(3%) had 
periodontitis, whereas 20 (6%) were smokers and two individuals (1%) had styalgia and hence 
were excluded.   Cases constituted, 71 patients in whom we could not detect any cause for 
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chronic pharynitis by history, clinical or endoscopic examination, were recruited as cases for the 
study. 
 Of the 71 patients recruited, 45 [63.4%] were males and 26 [36.6%] were females. The 
mean age of the cases was 34.8 years (range 18-65 years). The age wise distribution of the 
subjects enrolled is as given in the figure below (Fig 1). An equal number of controls who were 
matched for both age and sex with the patient group were also studied.   
 
Figure 2: Age and Sex distribution of cases 
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 The age distribution in males ranged from 18-62 yrs with a mean age of 34.13 yrs while 
inI females it ranged from 18-65 years with a mean of 35.96 years. 
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 Among the males, the most common age group was 27 to 36 while in females it was a 
decade later in the age group 37-46. Cases recruited were most commonly from the state of West 
Bengal (43.7) followed by Tamil Nadu (36.6%).and Andhra Pradesh (2.8%) 
 
Figure 3 - Mean duration of symptoms in cases 
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 Mean duration of throat irritation was19.27 months (standard deviation 25.14) whereas 
mean duration of throat pain was 6.56 months (standard deviation17.8). Chronic throat irritation 
was the most frequent complaint associated with persistent throat pain in 28 of the patients. Only 
3 patients presented with exclusive persistent throat pain 
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 Of the 71 patients almost all of them had taken treatment with medicated gargles. Almost 
50 % (35 of 71) of the patients had received more than one course of antibiotics. These 
antibiotics mainly belonged to the penicillin group. 
 
The results of the various tests performed on both cases and controls are as below     
Table 1: Results of tests performed on cases and controls  
 
Test done 
 
Results of tests done 
Cases (n=71)                           Controls (n=71) 
Positive (%) Negative (%) Positive (%) Negative (%) 
 
Aerobic culture 
 
9 
 
62 
 
9 
 
62 
 
Anaerobic Culture 
 
24 
 
47 
 
36 
 
35 
C. pneumoniae  
IgA ELISA  
 
35 
 
36 
 
16 
 
55 
M. pneumoniae 
IgA ELISA 
 
16 
 
55 
 
16 
 
55 
 
 It is clear from the above table that there was no significant difference between cases and 
controls with regard to growth of aerobes on aerobic culture and serological assays for 
Mycoplasma pneumoniae.The statistical analysis done using the chi square test and the Fisher’s 
exact test further support the lack of significance of aerobic organisms and Mycoplasma 
pneumoniae as probable etiological agents of chronic pharyngitis.  
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 IgA ELISA for C.pneumoniae was positive in 35 cases and 16 controls.  This difference 
in IgA ELISA positivity between cases and controls is found to be statistically significant 
(p=0.001) by the chi square test. Anaerobes were grown in 36 controls whereas only in 24 cases 
anaerobic organisms could be isolated. Analysis by chi square test has shown this finding to be 
statistically significant (p= 0.004).  
 
Table 2: List of aerobic organisms isolated from cases and controls 
Aerobic organisms isolated Cases Controls 
H influenzae 4 1 
H parainfluenzae 3 0 
S. aureus 2 3 
S. pneumoniae 3 2 
Β haemolytic streptococci 0 3* 
 
* Includes one isolate each of group A, B & C streptococci 
 Table 2 shows the number and type of aerobic organisms isolated from both cases and 
controls. 3 patients showed infection with 2 organisms. H. influenzae was isolated from four 
cases and one control. Whereas no β haemolytic streptococci were detected amongst the cases, 
H. parainfluezae could be isolated only from cases. 
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Table 3: List of anaerobic organisms isolated from cases and controls 
 
Anaerobic organisms 
isolated 
Cases  (28 of 71) Controls  (50 of 71) 
Fusobacterium spp. 15 28 
Anaerobic GPC (AGPC)* 13 22 
Anaerobic GPC: Anaerobic gram positive cocci 
 
 Only two types of anaerobes could be identified by culture as seen above (Table 3). 
Interestingly we observed higher rate of isolation in controls as compared to cases.  Among all 
the Fusobacterium spp. isolated from both cases and controls none could be identified as 
Fusobacterium necrophorum. Among the symptomatic individuals 4 who were anaerobic culture 
positive grew both Fusobacterium and Anaerobic GPC. In contrast 14 individuals among the 
control group grew both these organisms. 
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Table 4: Analysis of results of aerobic culture 
 Cases Controls 
Aerobic culture positive 9 (12.7%) 9 (12.7%) 
Aerobic culture negative 62 (87.3%) 62 (87.3%) 
TOTAL 71 71 
 P value = 1.000 
 Table 4 In the aerobic culture there is no significant difference (p=1.000) between the 
cases and controls as shown above.12.7% of both cases and controls showed positive growth on 
aerobic culture. 
Table 5: Analysis of results of anaerobic culture 
 Cases Controls 
Anaerobic culture positive 24 (33.8%) 36 (50.7%) 
Anaerobic culture negative 47 (66.2%) 35 (49.3%) 
Total 71 71 
    P VALUE = 0.041 
 A significant difference (P=0.041) in the anaerobic growth culture between the cases and 
controls is present as depicted in Table 5. In 24 (33.8%) of the cases and 36 (50.7%) controls, 
anaerobes were isolated from culture. 
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Table 6: Analysis of Fusobacterium spp. growth in cases and controls 
Anaerobic organism Cases Controls 
Fusobacterium spp positive 15 (21.1%) 28 (39.4%) 
Fusobacterium spp negative 56 (78.9%) 43 (60.6%) 
 
 Table 6 depicts the isolation of Fusobacterium spp. in anaerobic culture. A significant 
difference in the rate of isolation (P=0.018) between the cases and controls is observed.  
Fusobacteria were isolated in 21 % of the cases and 39% of the controls. It is evident using the 
Chi-square test that the frequency of isolation was significantly more in controls as compared to 
cases. 
Table 7 Analysis of results of IgA ELISA against Chlamydia pneumoniae 
 Cases Controls 
Chlamydia positive 35 (49.3%) 16 (22.5%) 
Chlamydia negative 36 (50.7%) 55 (77.5%) 
Total 71 71 
 
 The above table clearly shows the results of the serological tests (IgA ELISA) for 
Chlamydia pneumoniae performed on both cases and controls. IgA antibodies were detected 
more often among cases than the controls, i.e. 35 (49.3%) of cases were positive in contrast to 16 
(22.5%) of the controls. The higher number of positive results among cases in comparison to the 
same amongst controls was found to be statistically significant (P=0.001). 
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Table 8: Analysis of results of IgA ELISA against Mycoplasma pneumoniae 
 Cases Controls 
Mycoplasma antibody positive 16 (22.5%) 16 (22.5%) 
Mycoplasma antibody negative 55 (77.5%) 55 (77.5%) 
Total 71 71 
 
 This table (Table 8) clearly provides information that the IgA ELISA results for 
individuals with chronic pharyngitis and normals showed no statistically significant difference 
(P=1.000). An equal number of cases and controls were positive by this test.  
Table 9 Correlation between duration of throat irritation and organism isolated in cases 
Offending 
organism 
Positive Negative 
Z value p value Mean 
duration 
in months 
SD 
Mean 
duration 
in months
SD 
Anaerobic 20.46 27.7 18.6 24.0 -0.11 0.912 
Chlamydia 25.94 30.35 12.78 16.79 -2.45 0.014* 
Mycoplasma 19.75 29.02 19.13 24.2 -0.76 0.939 
 
 The mean duration of throat irritation in months among the cases and its relation to the 
organism isolated is seen above.  
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 Anaerobic culture positive patients had a mean duration of 20.46 months as compared to 
anaerobic negative individuals who has a mean duration of 18.6 months. Mycoplasma positive 
patients showed a mean duration of symptoms of 19.75months whereas it was 24.2 months in 
mycoplasma negative patients. Both the above values were not statistically significant. In 
contrast the duration of throat irritation was statistically higher (p=0.014) in cases who were 
seropositive for Chlamydia (25.9 months) as compared to those were seronegative.  
 
Table 10 Correlation between duration of throat pain and organisms detected in cases 
Offending 
organism 
Positive Negative 
Z value p value 
Mean SD Mean SD 
Anaerobic 11.00 27.03 4.3 10.08 -0.627 0.530 
Chlamydia 7.46 22.4 5.6 11.9 -1.18 0.235 
Mycoplasma 10.3 29.5 5.47 12.7 -0.237 0.813 
 
 Table 10 shows the mean duration of throat pain in months amongst the cases and its 
relation to a positive result for the three organisms evaluated.   No statistically significant 
(p=0.014) difference was observed in cases who were positive compared to those who were 
negative for the same.  
 
 
   47
Table 11- Association between organism isolated and chronic pharyngitis 
Offending organism Odd’s ratio P value 
Aerobic culture 1.134 0.821 
Anaerobic culture 0.435 0.026 
Chlamydia 4.158 0.001 
Mycoplasma 0.624 0.304 
 
 The odds ratio calculation showed that statistically relevant odds were only observed for 
positive anaerobic culture and Chlamydia serology. It is to be noted that there is an inverse 
relation with regard to isolation of an anaerobe by culture in the cases when compared to the 
controls. In individuals with chronic pharyngitis a direct relation between obtaining a positive 
serological result and the presence of symptoms is seen.   
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DISCUSSION 
 Chronic pharyngitis is a common clinical condition seen by both general practitioners and 
ENT physicians. Despite detailed evaluation, the most frequently encountered scenario is of a 
patient with persistent sore throat in whom no obvious cause can be elicited clinically. Although 
the literature abounds in published reports on the aetiology of acute pharyngitis there is a paucity 
of data on chronic pharyngitis. This study aimed to determine the clinical and microbiological 
profile of patients with chronic pharyngitis with special emphasis on the role of atypical 
organisms such as Mycoplasma pneumoniae, Chlamydia pneumoniae and Fusobacterium 
necrophorum. These organisms were specially looked for due to recent reports implicating them 
in chronic pharyngitis (4-6).  
 
 In the current study chronic non specific pharyngitis was the most common etiological 
type encountered among the 344 chronic pharyngitis patient’ screened. Laryngopharyngeal 
reflux was the commonest cause of chronic pharyngitis in this group followed by allergic rhino 
sinusitis and tobacco consumption. Chronic pharyngitis secondary to tuberculosis, syphilis or 
any other specific etiological agent was not seen in our study. This was probably because we 
selected our patients from a general ENT clinic whereas such patients are more likely to report in 
a general medical clinic with throat symptoms often neglected in the midst of other grave 
symptoms.   
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 Of the 344 patients screened, in 71 patients no cause was found on clinical and 
endoscopic examination. These patients were included as cases and an equal number of age and 
sex matched controls were included in the study. 
 
 Having studied the clinical and microbiological profile of patients with chronic 
pharyngitis in this group, we found this condition to be more predominant in the third decade 
(mean age male 34.13 years, female 35.96 years) with males more commonly affected than 
females (male 64%, female 36%). The average duration of throat irritation was 19.27 months and 
of throat pain was 6.56 months. A granular pharyngeal wall was the most common clinical 
finding on examination followed by an erythematous posterior pharyngeal wall. In all the above 
patients the examination of the tonsil and tonsillar pillars was normal. 
 The aerobic culture from the throat swabs from the posterior pharyngeal wall of both 
cases and controls revealed a plethora of organisms; however no significant difference was noted 
between cases and controls. None of the cases grew Group A β haemolytic streptococci in the 
throat swab culture which is the only known pathogen to have chronic carriage in the pharynx.ref 
Thus a throat swab for aerobic culture does not seem to be a useful investigation in the 
evaluation of patients with chronic pharyngitis. 
 In the evaluation of the anaerobic culture of the throat swabs contrary to the expected 
results we found that the isolation of anaerobic organisms was significantly more in controls  
(p=0.041) as compared to cases. None of the Fusobacterium spp. we isolated could be identified 
as Fusobacterium necrophorum. In recent times, Batty et al (2005) have opined that these 
organisms are responsible for longstanding sore throat in the general population. They isolated 
F.necrophorum from 21% of patients with persistent sore throat (6).  In the current study we did 
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not find any such association. Interestingly we found that the isolation of Fusobacterium spp. 
among controls was significantly higher in comparison to the cases (p=0.018). We believe that 
the increased isolation of anaerobes in healthy controls as compared to subjects with chronic 
pharyngitis is probably due to the prolonged use of medicated gargles and multiple courses of 
antibiotics received by these patients prior to treatment at our institute. Anaerobes are 
commensals in the oral cavity and susceptible to action of oral penicillins. Prolonged use of 
medicated gargles can cause a change in the oropharyngeal flora. 
 Serology for Mycoplasma pneumoniae did not demonstrate any significant difference. 
Beaver and Karow et al had demonstrated 15% of patients with chronic pharyngitis to have 
elevated IgM to mycoplasma pneumoniae. In our study the incidence of mycoplasma in cases 
and healthy controls was equal. Although a known case of acute pharyngitis its role in chronic 
pharyngitis needs further evaluation. More sensitive tests like cell culture may help in presenting 
a clearer picture of the role of this organism. However it is expensive and cumbersome and were 
beyond the scope of this study.  
 A statistically significant difference between the cases and the controls was noted only 
with Chlamydia pneumoniae serology .We found the difference in the percentage of subjects 
with positive serology to Chlamydia to be significantly (p =0.001) higher in patients included as 
cases (49.3%) as compared to controls (22.5%). An odds ratio of 4.1 (p=0.001) suggested that a 
patient seropositive for Chlamydia is four times more likely to be a case of chronic pharyngitis 
than a seronegative patient. In a similar study done by Falck et al they had demonstrated that 
75% (9 out of 12) of the patients with chronic pharyngitis had positive IgA antibodies to 
C.pneumoniae. However their study was limited by small sample size (n = 12) and lack of 
controls (5). 
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 Clinically we observed a granular posterior pharyngeal wall in 54 of our 71 patients 
(73%) as compared to 3 of 71 subjects in our control group (4%). All patients with antibodies 
against Chlamydia had a granular posterior pharyngeal wall. This granular appearance may be 
the result of the body’s response to infection with Chlamydia pneumoniae.  Falck et al had 
demonstrated positive immunohistochemistry for Chlamydia in the granulations from the 
posterior pharyngeal wall in 9 of the 12 patients in their study (5). 
 
 We found that the duration of throat irritation was significantly higher (p=0.014) in 
individuals with chronic pharyngitis who had a seropositive result for c. pneumoniae than in 
those who were seronegative. In contrast there was no association between the period of throat 
pain and detection of Chlamydia in cases. No statistically significant correlation between these 
symptoms and a positive result for mycoplasma serology and anaerobic culture was observed 
amongst those with chronic pharyngitis.   
 Asymptomatic carriers of Chlamydia in the respiratory tract are well described .This was 
first illustrated by Gnarpe et al who found a prevalence of 4.7% in throat of healthy adults using 
cell culture techniques(68). Similar results were obtained by Emre et al and Block et al who 
detected C.pneumoniae by cell culture in 4.9% and 5% of healthy asymptomatic children (ref). 
Using serological methods Kern et al have reported prevalence of 12.9% in healthy subjects 
(ref). In our study 22.5% of the healthy controls had IgA antibodies to C. pneumoniae by ELISA. 
This difference in the prevalence could be because of the use of a different cohort from a 
different geographical area than employed in their study.  
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 We employed IgA antibody as it is a better marker for the detection of persistent 
infection. IgG antibodies are long lasting hence an elevated IgG titre does not give any 
information if the antibodies are due to past infection or due to a persistent one. IgA antibodies 
being short lived; elevated titres suggest a persisting infection. 
 
 There are limited studies on the treatment of these chlamydial infections as the diagnosis 
is by serology and therefore difficult to assess efficacy of treatment. In the few studies reported 
(5, 60, 66) treatment has been unsatisfactory in terms of eradication of these bacteria.  In the study 
done by Roblin et al the efficacy of erythromycin and clarithromycin was similar in terms of 
clinical improvement; however both could not completely eradicate the organism as proved by 
cell culture methods. In-vitro studies suggest clarithromycin to be better in terms of tissue 
penetration. This dichotomy in clinical resolution and microbiological persistence suggests that 
the persistence is not secondary to the development of antibiotic resistance. The persistent nature 
of chlamydial infections can probably be explained by its unique life cycle. The infectious 
particle is the elementary body (EB) which after entering the cell develops into the metabolically 
active reticulate body (RB) (58). Only the metabolically active chlamydia1 forms are affected by 
antibiotics that penetrate intracellular spaces like the macrolides or tetracyclines. The infectious 
particle of Chlamydia, the elementary body, is metabolically inert and therefore resistant to the 
action of bacteriostatic antibiotics such as macrolides and tetracycline’s (68). This explains the 
commonly encountered clinical situation wherein patients with chronic pharyngitis show 
improvement of symptoms for a short period while on antibiotics and for a short period of time 
thereafter, before they have a relapse of symptoms. 
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 In spite of the various mechanisms described the exact molecular mechanism of 
chlamydial persistence is not known. There is hope that the mechanism of persistence will soon 
be unravelled by using tools such as proteomics, and microarrays.  
 Gnarpe et al and Hammerschlag et al have noted that chronic persistent infection by 
Chlamydia may be difficult to eradicate with a single course of antibiotics (66, 68). Falck et al 
suggest that the immune mechanisms may in most patients eliminate the organism (5). There are 
animal studies that propose that induction of mucosal IgA immune response by local 
immunization may be the future of treatment of chronic pharyngitis (Rodrigues et al 2005). 
 We suggest that local measures such as medicated gargles for a prolonged duration (3 
months) may be a solution to this clinical problem although  placebo controlled double blinded 
trials are needed to further study this.  
 Beaver and Karow et al (4) have inferenced that individuals with allergies and silent 
laryngopharyngeal reflux have a more fragile pharyngeal mucosa and consequently more prone 
to infection with Chlamydia. We in our study have not attempted to study the role of atypical 
organisms in patients with allergies and Laryngopharyngeal reflux. This could be the subject of 
another study 
Limitations of the study 
1. We were unable to identify the species of fusobacteria isolated in our study. Therefore 
our study does not provide any data regarding whether Fusobacterium necrophorum 
was the predominant species in either cases or controls. Fusobacterium necrophorum 
was the main offending organism in persistent sore throat in study by Batty et al. 
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CONCLUSION 
 Chronic pharyngitis is a common clinical condition seen predominantly in the second and 
third decades affecting males more commonly than females. Though a paucity of data exists on 
the case definition of this condition it is most commonly defined by its most predominant 
symptom i.e persistent sore throat and the presence of prominent lymphoid follicles in the 
posterior pharyngeal wall. A structured history taking and thorough clinical examination is 
needed for evaluation of these patients with exclusion of malignancy being the main priority.  
Pharyngitis secondary to specific disease conditions such as tuberculosis, syphilis, HIV etc are 
easy to diagnose due to its association with multiple organ systems. Chronic non specific 
pharyngitis is the most common clinical type encountered in our outpatients. Laryngopharyngeal 
reflux was the commonest cause of chronic non specific pharyngitis in this study. Such patients 
have typical history and clinical findings which can be recognised and treatment instituted. Other 
common causes of chronic pharyngitis such as allergies and asthma, environmental and 
occupational irritants and dental sepsis should be borne in mind and appropriately addressed. 
 
 The common bacteriological agents usually incriminated in causing pharyngitis such as β 
hemolytic streptococci, staphyococcus aureus and streptococci pneumoniae were not a 
significant cause of chronic pharyngitis in our study. Infection with chlamydia pneumoniae 
seems to be a significant etiological factor for chronic pharyngitis. Granulations on the posterior 
pharyngeal wall should alert the clinician on the possibility of this infection. Granulations on the 
posterior pharyngeal wall should alert the clinician on the possibility of this infection. These 
infections are not susceptible to the commonly given penicillin group of antibiotics. Response 
with macrolide group of antibiotics is good though short lived. This is probably secondary to the 
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persistence of this organism in a viable but non infectious form on which the antibiotics fail to 
act. The commonly encountered clinical situation wherein patients with chronic pharyngits show 
improvement of symptoms for a short period while on antibiotics before they have a relapse of 
symptoms can be explained because of action of antibiotics on the infectious elementary body 
and not on the dormant non infectious reticulate body. Studies where long term follow up can be 
undertaken should be done to assess the best modality of treatment of this infection. 
 Anaerobic organisms did not seem to be significant etiological agent of chronic 
pharyngitis in this study .On the other hand a reduction in the commensal anaerobic flora of the 
pharynx was noted in these patients. This could be due to prolonged use of medicated gargles 
and repeated courses of antibiotics which the patients had received prior to treatment at our 
institute. Medicated gargles can also cause a change in the oropharyngeal flora. The inability to 
speciate Fusobacterium was a limitation of this study and further studies with research laboratory 
facilities are needed to study the role of anaerobic bacteria in persistent sore throat. 
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APPENDIX A- CLINICAL PROFORMA 
 
 
Date 
Name 
Age 
Sex 
Hospital number 
Place 
Throat irritation                                                         YES/NO               DURATION 
Throat pain                                                                YES/NO              DURATION 
Dysphagia                                                                  YES/NO               DURATION 
 
History of allergic rhinitis 
Bilateral alternating nasal block                                YES /NO                 DURATION 
History of excessive sneezing                                    YES/NO                  DURATION 
Post nasal drip                                                            YES/NO                  DURATON 
History of asthma 
Wheezing                                                                   YES/NO                  DURATION 
Dry cough                                                                  YES/NO                  DURATION 
HISTORY OF ACID REFLUX DISEASE 
Heartburn                                                                   YES/NO                  DURATION 
Regurgitation of sour fluid                                         YES/NO                 DURATION 
Frequent throat clearing                                             YES/NO                 DURATION 
Hoarseness of voice                                                   YES/NO                 DURATION 
Globus sensation                                                        YES/NO                 DURATION 
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History of   Smoking                                                  YES/NO                 DURATION 
History of tobacco consumption                               YES/NO                 DURATION 
History of HTN /DM/Asthma                                     YES/NO                 DURATION 
                                                                                    MEDICATION      DURATION 
History of previous treatment                                    YES/NO 
Medical                                                                       YES/NO 
Surgical                                                                       YES/NO 
 
EXAMINATION 
PULSE 
BP 
CHEST                                                                      NORMAL/ WHEEZE/OTHERS 
NOSE        
     PALE NASAL MUCOSA                                   YES/NO 
      NASAL   DISCHARGE                                      YES/NO 
ORAL 
      DENTAL HYGEINE                                           GOOD/FAIR/POOR 
      ORAL ULCER /LESION                                    YES/NO 
      TONSIL                                                                GRADE 1/2/3 
  PPW                                                                       ERYTHEMA/GRANULAR/NOMAL 
 
INDIRECTLARYNGOSCOPY                        NORMAL/LPR/MASSLESION/OTHERS 
 
RIGID NASAL ENDOSCOPY                         NORMAL/ALLERGIC RHINITIS /  
                                                                               CHR SINUSITIS/OTHERS 
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NASOPHARYNGOLARYNGOSCOPY          IF DONE FINDINGS                                                                      
 
AEROBIC CULTURE                                     NORMAL FLORA 
                                                                          ORG 1                  TYPE OF GROWTH 
                                                                          ORG 2                   TYPE OF GROWTH 
 
 ANAEROBIC CULTURE                                     NO ANAEROBES 
                                                                          ORG 1                  TYPE OF GROWTH 
                                                                          ORG 2                   TYPE OF GROWTH 
 
ELISA FOR CHLAMYDIA                              VALUE 
                                                                            NEGATIVE/POSITIVE 
 
ELISA FOR MYCOPLASMA                            VALUE 
                                                                             NEGATIVE/POSITIVE 
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INFORMATION SHEET 
Study Title ; Evaluation of the bacteriological and clinical profile of chronic pharyngitis 
with emphasis on studying the potential role of atypical pathogens as etiological agents 
Purpose of research  
 You have been diagnosed to have long standing sore throat. This study will provide 
information about possible causes of this condition. We will collect information regarding your 
complaints. You will undergo an ENT examination during which throat samples and serum will 
be collected for testing. All these tests are routine and will not result in any extra cost or harm 
you in any way. 
Expected duration of the Subject’s participation  
 If you have long standing sore throat, you will required to come for follow up in the ENT 
OPD after 15 days. 
Description of the procedures 
 Procedures or therapies for management of disease will remain same (same as any other 
patient who is not involved in the study, and will include ENT examination, blood investigation 
and throat sample testing). There are no invasive procedures involved. A set of normal people 
without any throat complaints will be examined and will have to undergo the same tests and then 
the results will be compared. 
Risks or discomforts to the Subject  
 As the study doesn’t include any trial treatment, there is no extra risk for you due to your 
participation in the study. 
Benefits to the Subject  
 The benefit of this study to you is that the doctors treating your condition will be better 
informed regarding the causes of this illness. This may indirectly affect your treatment. 
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Benefits to others  
 This will help us to understand the problem better and will help us to find out the most 
cost effective method of detection of the causes for this condition. We hope that the knowledge 
obtained will help us to improve the quality of care given to individuals with this type of illness 
at our centre. 
Confidentiality   
 Your identity will be strictly kept confidential and may be published in a scientific 
journal. No one other than the treating doctors and the investigators of this study shall have 
access to your medical records.  
Participation  
 Your participation in the study is voluntary and you are free to withdraw at any time, 
without giving any reason. Refusal to participate in the research study will not involve any 
penalty or loss of benefits to which you are otherwise entitled. 
Cost to the Subject  
 There is absolutely no additional cost to you as a result of participation in this study. 
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APPENDIX B -INFORMED CONSENT FORM 
 
Informed Consent form to participate in a clinical trial 
 
Study Title: Evaluation of the bacteriological and clinical profile of chronic pharyngitis with 
emphasis on studying the potential role of atypical pathogens as etiological agents 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______                            Phone no.: 
Please initial box  
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I 
understand that my identity will not be revealed in any information released to third parties or 
published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such a 
use is only for scientific purpose(s) [ ] 
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(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
 







